Information on this page is intended for UK healthcare professionals only and may contain promotional material
Tillotts in the UK
Tillotts Pharma UK is proud to be based in Lincolnshire and is the largest wholly owned affiliate of Switzerland based Tillotts Pharma AG, part of the Japanese Zeria Group.
GI health is our passion at Tillotts
With over 30 years’ expertise in developing and manufacturing treatments for inflammatory bowel disease (IBD), we understand the disease, the market and the challenges GI healthcare professionals and patients face.
Tillotts Pharma UK is a market leader in GI health products and provides support in the following areas:
- Inflammatory Bowel Disease
- Clostridioides difficile Infections
Enhancing patient care
Tillotts Pharma UK strive to be the preferred partner in GI health and are committed to supporting the NHS to improve outcomes for patients. Tillotts are motivated by the aim to consistently deliver quality and value to the NHS and are dedicated to improving the lives of people with GI disease and supporting those who care for them.
Supporting healthcare professionals
We’re committed to supporting our healthcare colleagues where possible, which is why we created our educational programs for healthcare professionals working in the areas we specialise in.
We also support external congresses and events that provide valuable learning opportunities for UK healthcare professionals and sponsor individual attendance where appropriate.
An award-winning organisation
Tillotts Pharma UK has received several industry-recognised awards, most recently a 2025 Communiqué award within the “Excellence in National or Local Education Meetings/ Stand-Alone Events” category.
TPUK were also winners of the 2024 Pharmaceutical Market Excellence Awards “Excellence in Engaging and Educating Healthcare Professionals” category, 2024 Pharma Industry “Supply Chain Achievement Award”, a Gold Communiqué Award in 2019, Gold and Silver PM Society Awards in 2018 and were awarded the first Tillotts Star award. This award recognized the growth and development of Tillotts UK, which is now Tillotts largest affiliate
Seeking partnerships
Tillotts actively seeks partnership and in-licensing opportunities to add to our portfolio of medicines. We are particularly interested in products that may be off-patent or are currently not being actively promoted, where we can breathe life back into the brand, help fulfil any unmet patient needs, and provide value to the NHS.
Case studies and testimonials are available on request for interested parties.
NU-02901 | August 2026
The information on the following pages is intended only for UK resident patients who have been prescribed Octasa, fidaxomicin, Entocort Enema, or budesonide CR 3 mg Capsules.
The following pages are not a substitute for advice from a healthcare professional. Please read the patient information leaflet included with your medication and speak to your doctor, nurse, or pharmacist if you have any questions.
Adverse events should be reported. Reporting forms and information can be found at yellowcard.mhra.gov.uk.
Adverse events should also be reported to Tillotts Pharma UK Ltd on 01522813500 or uksafety@tillotts.com
You are about to leave tillotts.co.uk for an external website. Tillotts is not responsible for the content of other websites.